Ardelyx Reports Strong 2025 Revenue And Outlook

Ardelyx, Inc. reported preliminary unaudited product revenue results for fourth quarter and full-year 2025, saying Ibsrela revenue rose 73% year-over-year and Xphozah sales increased. The company announced a Phase 3 program for Ibsrela in chronic idiopathic constipation, initiation of next-generation NHE3 inhibitor RDX10531, and guidance anticipating continued growth and Ibsrela peak sales exceeding $1 billion, with patent protection through 2041.